Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics (FATE) reported fourth-quarter 2023 loss of 45 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents and the year-ago loss of 58 cents.The loss narrowed year over year due to lower research and development (R&D) expenses.The company earned collaboration revenues of $2 million, which also surpassed the Zacks Consensus Estimate of $1 million but was down from $44 million reported in the year-ago quarter.Revenues were derived from the company’s preclinical developm ...